LDC7559
Based on 23 publication(s) in Google Scholar
LDC7559 is a gasdermin D (GSDMD) inhibitor via blocking neutrophil extracellular trap (NET) in the late stages .
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.51%
- CAS No.: 2407782-01-6
- Formule: C20H19N3O3
- Masse moléculaire:349.38
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
Pyroptosis Compound Library
HY-L059
-
Targeted Diversity Library
HY-L099
-
Heterocyclic Compound Library
HY-L138
-
Cell Death Library
HY-L162
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) LDC7559
More- Autophagy. 2025 May;21(5):934-956. [Abstract]
- Nat Cardiovasc Res. 2024 May;3(5):525-540. [Abstract]
- Stroke. 2024 Nov;55(11):e297-e299. [Abstract]
- Free Radic Biol Med. 2025 Sep:237:503-514. [Abstract]
- J Agric Food Chem. 2024 Nov 13;72(45):25173-25185. [Abstract]
- Life Sci. 2023 Nov 1:332:122123. [Abstract]
- Int Immunopharmacol. 2026 Jun 1:178:116578. [Abstract]
- Cancer Sci. 2025 Mar;116(3):673-689. [Abstract]
- FASEB J. 2020 Oct;34(10):14024-14041. [Abstract]
- Eur J Immunol. 2025 Apr;55(4):e202350942. [Abstract]
- Eur J Immunol. 2023 Jan;53(1):e2250011. [Abstract]
- Naunyn Schmiedebergs Arch Pharmacol. 2025 Apr 16. [Abstract]
- Viruses. 2025 Nov 12;17(11):1492. [Abstract]
- J Pharmacol Sci. 2025 Dec;159(4):256-267. [Abstract]
- J Med Microbiol. 2024 Dec 26:318:151642. [Abstract]
- Mol Cell Toxicol. 2025 Dec 8.
- bioRxiv. 2026 Mar 3.
- Radiat Med Prot. 2024 May 23.
- Research Square Preprint. 2024 Jan 19.
- Cell Mol Biol (Noisy-le-grand). 2023 Oct 31;69(10):227-232. [Abstract]
- Research Square Preprint. 2023 Aug 7.
- Research Square Print. 2023 Mar 14.
- Elife. 2021 Jul 21:10:e68755. [Abstract]
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
Bio/Physico-chemical Assay
-
Cell Proliferation/Viability Assay
-
Cell Imaging/Staining
-
IP
Activité biologique
Gasdermin D[1].
LDC7559 (1 and 5 μM) inhibits IL-1β release upon inflammasome activation, and significantly blocks the lethal effect of both human and murine GSDMD NT domains transfected into HEK293T cells[3].
LDC7559 functions directly through blocking the activity of the GSDMD NT domain, rather than interfering with the activation and cleavage process[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 2407782-01-6
-
Appearance Solid
-
Masse moléculaire 349.38
-
Formule C20H19N3O3
-
Color White to light yellow
-
SMILES
COC1=C(C=CC=C1)C2=NN3C(COC(C=C(NC(C)=O)C=C4)=C4C3)=C2
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (23)
-
Journal Impact Factor
-
Most Recent
-
Autophagy
2025 May;21(5):934-956. PMID: 39663580
LDC7559 purchased from MedChemExpress. Usage Cited in: Autophagy. 2025 May;21(5):934-956. [Abstract]
LDC7559 (5 μM; 2+24 h)did not prevent cell death induced by indatraline and sertraline. U2OS cells were preincubated with a specific inhibitor for pyroptosis, LDC7559 (5 μM), for 2 h and then treated with indatraline (10 μM) or sertraline (10 μM) for 24 h.
-
Nat Cardiovasc Res
Stroke and myocardial infarction induce neutrophil extracellular trap release disrupting lymphoid organ structure and immunoglobulin secretion. [Abstract]2024 May;3(5):525-540. PMID: 39195931 -
Stroke
Delayed DNase-I Administration but Not Gasdermin-D Inhibition Induces Hemorrhagic Transformation After Transient Focal Cerebral Ischemia in Mice. [Abstract]2024 Nov;55(11):e297-e299. PMID: 39344516 -
Free Radic Biol Med
p67phox/NOX2 inhibits psoriasis by regulating the HIF-1α-glycolysis axis via p53-AMPK in keratinocytes. [Abstract]2025 Sep:237:503-514. PMID: 40516795 -
J Agric Food Chem
Integrative Gut Microbiota and Metabolomic Analyses Reveal the PANoptosis- and Ferroptosis-Related Mechanisms of Chrysoeriol in Inhibiting Melanoma. [Abstract]2024 Nov 13;72(45):25173-25185. PMID: 39497239 -
Life Sci
Phosphate burden induces vascular calcification through a NLRP3-caspase-1-mediated pyroptotic pathway. [Abstract]2023 Nov 1:332:122123. PMID: 37742736
LDC7559 purchased from MedChemExpress. Usage Cited in: Life Sci. 2023 Nov 1:332:122123. [Abstract]
LDC7559 (2.5 μM; 8 days) and disulfiram, attenuated VSMC calcification. Alizarin red staining of A7r5 cells in HP or control medium for 8 days treated with LDC7559 (2.5 μM), disulfiram (5 nM), or IL-1RA (5 μM) (scale bar 100 μm). The results were semi-quantified by the concentrations of Alizarin red.
LDC7559 purchased from MedChemExpress. Usage Cited in: Life Sci. 2023 Nov 1:332:122123. [Abstract]
LDC7559 (2.5 μM; 8 days) treatment attenuated the cleavage of GSDMD and the release of LDHA in VSMCs subjected to a phosphate burden, indicating that pyroptosis was prevented. Immunoblots of A7r5 cell lysates and supernatants after 8 days of LDC7559 treatment.
-
Int Immunopharmacol
Neutrophil aconitate decarboxylase 1/itaconate axis suppresses extracellular traps via alkylating GSDMD and alleviates murine liver injury. [Abstract]2026 Jun 1:178:116578. PMID: 41915992 -
Cancer Sci
BCR::ABL1-induced mitochondrial morphological alterations as a potential clinical biomarker in chronic myeloid leukemia. [Abstract]2025 Mar;116(3):673-689. PMID: 39652455
LDC7559 purchased from MedChemExpress. Usage Cited in: Cancer Sci. 2025 Mar;116(3):673-689. [Abstract]
LDC7559 (10 μM; L； 72 h) inhibited Mdivi‐1‐induced cell death in both BCR::ABL1‐positive and BCR::ABL1‐negative cells. Cell viabilities, live cell counts, and dead cell ratios were evaluated after 72 h of Mdivi‐1 treatment with or without inhibitors. Inhibitors used included: Caspase inhibitor Z‐VAD‐FMK (Z); gasdermin D inhibitor LDC7559 (L); necroptosis inhibitor Necrostatin‐1 (N); ferroptosis inhibitor Ferrostatin‐1.
-
FASEB J
Alum triggers infiltration of human neutrophils ex vivo and causes lysosomal destabilization and mitochondrial membrane potential-dependent NET-formation. [Abstract]2020 Oct;34(10):14024-14041. PMID: 32860638 -
Eur J Immunol
PLC and PAD2 Regulate Extracellular Calcium-Triggered Release of Macrophage Extracellular DNA Traps. [Abstract]2025 Apr;55(4):e202350942. PMID: 40170382
LDC7559 purchased from MedChemExpress. Usage Cited in: Eur J Immunol. 2025 Apr;55(4):e202350942. [Abstract]
LDC7559 (2 µM) and stimulated for 1 h with extracellular Ca2+ (1 mM). LDC7559 blocked inflammasome‐mediated pore formation.
-
Eur J Immunol
2023 Jan;53(1):e2250011. PMID: 36250416 -
Naunyn Schmiedebergs Arch Pharmacol
Astragaloside IV-PESV facilitates pyroptosis by enhancing palmitoylation of GSDMD protein mediated by ZDHHC1. [Abstract]2025 Apr 16. PMID: 40237800 -
Viruses
H6N6 Avian Influenza Virus Infection Induced Pyroptosis of M1 Macrophages by Activating Caspase-1. [Abstract]2025 Nov 12;17(11):1492. PMID: 41305513 -
J Pharmacol Sci
Endothelial NLRP3-mediated pyroptosis induces blood-brain barrier and neuronal damage in Huntington's disease models. [Abstract]2025 Dec;159(4):256-267. PMID: 41241436 -
J Med Microbiol
E. coli Nissle 1917 improves gut microbiota composition and serum metabolites to counteract atherosclerosis via the homocitrulline/Caspase 1/NLRP3/GSDMD axis. [Abstract]2024 Dec 26:318:151642. PMID: 39742694 -
-
-
-
-
Cell Mol Biol (Noisy-le-grand)
GSDMD inhibitor protects chondrocyte from mechanical injury in human articular cartilage. [Abstract]2023 Oct 31;69(10):227-232. PMID: 37953558 -
-
-
Elife
2021 Jul 21:10:e68755. PMID: 34292151
Solvant et solubilité
DMSO : 100 mg/mL (286.22 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (5.95 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (5.95 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (274 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Spel L, et al. Gasdermin D opens the way for NETs. Nat Rev Rheumatol. 2018 Dec;14(12):690-692. [Content Brief]
[2]. Sollberger G, et al. Gasdermin D plays a vital role in the generation of neutrophil extracellular traps. Sci Immunol. 2018 Aug 24;3(26). pii: eaar6689. [Content Brief]
[3]. Ankit Pandeya, et al. Gasdermin D (GSDMD) as a New Target for the Treatment of Infection. Medchemcomm. 2019 Apr 4;10(5):660-667. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.8622 mL | 14.3111 mL | 28.6221 mL | 71.5553 mL |
| 5 mM | 0.5724 mL | 2.8622 mL | 5.7244 mL | 14.3111 mL | |
| 10 mM | 0.2862 mL | 1.4311 mL | 2.8622 mL | 7.1555 mL | |
| 15 mM | 0.1908 mL | 0.9541 mL | 1.9081 mL | 4.7704 mL | |
| 20 mM | 0.1431 mL | 0.7156 mL | 1.4311 mL | 3.5778 mL | |
| 25 mM | 0.1145 mL | 0.5724 mL | 1.1449 mL | 2.8622 mL | |
| 30 mM | 0.0954 mL | 0.4770 mL | 0.9541 mL | 2.3852 mL | |
| 40 mM | 0.0716 mL | 0.3578 mL | 0.7156 mL | 1.7889 mL | |
| 50 mM | 0.0572 mL | 0.2862 mL | 0.5724 mL | 1.4311 mL | |
| 60 mM | 0.0477 mL | 0.2385 mL | 0.4770 mL | 1.1926 mL | |
| 80 mM | 0.0358 mL | 0.1789 mL | 0.3578 mL | 0.8944 mL | |
| 100 mM | 0.0286 mL | 0.1431 mL | 0.2862 mL | 0.7156 mL |
LDC7559 Related Classifications
HY-111674 Related Classifications
Powered by Bioz